An intravenous (IV) injection is an injection of a medication or another substance into a vein and directly into the bloodstream. It is one of the fastest ways to get a drug into the body, often ...
While some of the biologics require in-office administration, efalizumab and etanercept can be subcutaneously self-injected by the patient at home. Biologics requiring in-office administration IM or ...
An intramuscular injection is a technique for delivering medication deep into the muscles. This allows the medication to absorb quickly into the bloodstream. You may have received an intramuscular ...
Injections deliver liquid medications, fluids, or nutrients directly into a person’s body. Different types of injections include intravenous, intramuscular, subcutaneous, intraosseous, and intradermal ...
With Bristol Myers Squibb (BMS) now rolling out the SC version of rival nivolumab (Opdivo Qvantig), the shift from 30-minute intravenous (IV) infusion to 5-minute SC injection could be one of the most ...
To compare the pharmacokinetic parameters of cefuroxime lysine, a new second-generation of cephalosporin antibiotics, after intravenous (IV), intraperitoneal (IP), or intramuscular (IM) administration ...
The researchers have detailed their complete findings of subcutaneous (SC) vs intravenous (IV) efgartigimod in generalized myasthenia gravis (gMG) from the phase 3 ADAPT-SC trial and initial findings ...
Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patients, nurses and physicians1-5 Tecentriq SC ...
Credit: Getty Images. The SC formulation is intended to be administered in 10 minutes twice a year. Positive data were announced from a phase 3 trial evaluating an investigational subcutaneous (SC) ...
The Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Leqembi ® Iqlik ™, a once weekly lecanemab-irmb subcutaneous (SC) injection, for maintenance dosing to ...
Six out of 10 cancer patients who took part in a clinical trial preferred a subcutaneous injection formulation that improves the existing dosing method of Keytruda, an anticancer drug from Merck (MSD) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback